Category: Resources
-
ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients Read more here: http://www.sacbee.com/2012/10/25/4937522/abraxane-demonstrates-significant.html#storylink=cpy
MELBOURNE, Australia, Oct. 25, 2012 — /PRNewswire/ — Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel).…
-
ZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that compelling clinical activity was seen in its Phase 1 study of Ad-RTS IL-12, a novel DNA-based therapeutic candidate, in advanced melanoma. Based on early activity, and determination of a biologically effective dose, the Company also…
-
SA to ban tanning beds from 2015
Indoor tanning beds will be banned in South Australia because they increase the risk of melanoma by 20 per cent. Tanning beds in solariums will be banned in South Australia from 2015 because of health concerns. The ban will bring SA into line with NSW which will ban the beds from the same date. “There…
-
Two-drug combination best for melanoma
National report — A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers. The study demonstrated that the BRAF-inhibitor dabrafenib and the MEK-inhibitor trametinib resulted in a median progression-free survival of 9.4 months compared to 5.8 months for patients who received only dabrafenib,…
-
Melanoma: The Wolf in Sheep’s Clothing
Melanoma is so dangerous because it tends to metastasize early on. New treatment approaches utilize, among other things, the ability of the immune defense to search out and destroy malignant cells. Yet this strategy is often only temporarily effective. A research team under the direction of Bonn University has discovered why this is the case:…
-
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Background Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illustrated recently by the clinical experience with vemurafenib. Such acquired resistance appears to be the result of parallel pathway activation, such…
-
Checking For Skin Cancer: The ABCDE’s of Melanoma
“Checking your skin for skin cancer only requires your eyes and a mirror. Involving a partner adds another set of eyes, which is especially helpful when checking the back and other hard-to-see areas,” said Thomas E. Rohrer, MD, FAAD, a board-certified dermatologist in private practice in Chestnut Hill, Mass. “Examining your skin only takes a…
-
Dabrafenib in Patients With Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): A Multicentre, Open-Label, Phase 2 Trial
Abstract Background: Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain.Methods: We undertook a multicentre, open-label, phase 2 trial in 24 centres in six countries. We enrolled patients with…
-
IFN-gamma specifically targets melanoma stem cells and inhibits in vitro spherogenic growth
Cancer at its most fundamental level involves dysregulated and inexorable local and metastatic growth of abnormal cells, leading to patient mortality. The limited therapeutic benefit of current treatments is likely to relate to the existence of therapy-resistant, virulence-conferring cancer cell subpopulations. One of these subpopulations may coincide with Cancer Stem Cells (CSCs). CSCs are a…
-
Dual drug therapy delayed treatment resistance in melanoma
Two drugs being evaluated by the FDA slowed the development of treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein. http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/